5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 1, 2006, Pages 137-144

  Brunner, M ^a   Lackner, E ^a   Exler, P S ^c   De Fluiter, H C ^c   Kletter, K ^a   Tschurlovits, M ^b   Dudczak, R ^a   Eichler, H G ^a   Muller M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b TU WIEN   (Austria)

^c Disphar International BV Hengelo   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASAMAX; MESALAZINE;

ADULT; ARTICLE; ASCENDING COLON; CECUM; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRANSIT; HUMAN; ILEUM; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SCINTIGRAPHY; TABLET DISINTEGRATION; TABLET FORMULATION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; TABLETS;

EID: 33644929567     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02721.x     Document Type: Article

References (14)

1. Klotz U The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease Eur J Clin Pharmacol 2000 56 353 62
2. Hanauer SB Review article: aminosalicylates in inflammatory bowel disease Aliment Pharmacol Ther 2004 20 Suppl 4 60 65
3. Podolsky DK Inflammatory bowel disease N Engl J Med 2002 347 417 29
4. Klotz U Schwab M Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease Adv Drug Deliv Rev 2005 57 267 79
5. Qureshi AI Cohen RD Mesalamine delivery systems: do they really make much difference Adv Drug Deliv Rev 2005 57 281 302
6. Vree TB Dammers E Exler PS Maes RAA Multiple absorptions patterns of mesalazine from two gastroresistant tablets in healthy male volunteers Clin Drug Invest 2001 21 295 305
7. Committee for Proprietary Medicinal Products Note for guidance on the investigation of bioavailability and bioequivalence CPMP/EWP/QWP/1401/98 26.07.2001. (last accessed 30 October 2005).
8. Wilding IR Bioequivalence testing for locally acting gastrointestinal products: what role for gamma scintigraphy J Clin Pharmacol 2002 42 1200 10
9. Wilding IR Behrens C Tardif SJ Wray H Bias P Albrecht W Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects Aliment Pharmacol Ther 2003 17 1153 62
10. Brunner M Assandri R Kletter K et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation Aliment Pharmacol Ther 2003 17 395 402
11. 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers Aliment Pharmacol Ther 2003 17 1163 9
12. Sandborn WJ Hanauer SB Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and meslazine pro-drugs used in the management of ulcerative colitis Aliment Pharmacol Ther 2003 17 29 42
13. Bondesen S Bronnum-Schon J Pedersen V Rafiolsadat Z Honore Hansen S Huidberg EF Absorption of 5-aminosalicylic acid from colon and rectum Br J Pharmacol 1988 25 269 72
14. Schwab M Klotz U Pharmacokinetic considerations in the treatment of inflammatory bowel disease Clin Pharmacokinet 2001 40 723 51